MentionFox
Home › Executive changes › Maxcyte, Inc.
Leadership changes · MXCT · SEC Form 8-K, Item 5.02

Leadership changes at Maxcyte, Inc. (2026)

Before you join, sell to or invest in Maxcyte, Inc.

MentionFox check on Maxcyte, Inc.: only 2 sources on file so far (checked 14 November 2026). Run a full check before you rely on it. mentionfox.com/c/executive-changes/maxcyte

  • Note: Layoff plan disclosed Dec 2024 (filing)

New since last check: Layoff plan disclosed Dec 2024 (filing, first seen 14 November 2026).

Check Maxcyte, Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Maxcyte, Inc.?

Who joined and who left Maxcyte, Inc. (MXCT)? 1 appointment reported on 2026-03-27, each cited to the company's own filing.

Parmeet Ahuja was named Chief Financial Officer of Maxcyte, Inc., effective March 30, 2026. As of November 14, 2026, Maxcyte, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 27, 2026, naming 1 appointment (Form 8-K, March 27, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Capricorn Fund Managers Ltd also filed stake reports on 3 other companies ↓

Sell to companies like Maxcyte, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Changes1
In (appointed)1
Latest filing2026-03-27

Maxcyte, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-27. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Maxcyte, Inc. files it.

Layoffs on record: 1 filing or notice, latest 2024-12-09 (layoff filings and notices).

Also on the record for Maxcyte, Inc.

DateRecordFigureOur pageSource
November 2, 2026Stake report, Schedule 13D, by Liontrust Investment Partners LLP4.9% of the class5%+ stakesSource
October 15, 2026Stake report, Schedule 13D, by Liontrust Investment Partners LLP5% of the class5%+ stakesSource
August 4, 2026Stake report, Schedule 13D, by RIVER GLOBAL INVESTORS LLP0.8% of the class5%+ stakesSource
July 29, 2026Stake report, Schedule 13G/A, by BlackRock, Inc.1.3% of the class5%+ stakesSource
May 14, 2026Stake report, Schedule 13D, by RIVER GLOBAL INVESTORS LLP6.1% of the class5%+ stakesSource
April 10, 2026Stake report, Schedule 13G/A, by Mirabella Financial Services LLP—5%+ stakesSource
March 27, 2026Stake report, Schedule 13G/A, by The Vanguard Group—5%+ stakesSource
February 17, 2026Stake report, Schedule 13G/A, by Cadian Capital Management, LP3.5% of the class5%+ stakesSource
February 5, 2026Stake report, Schedule 13G, by Capricorn Fund Managers Ltd7.7% of the class5%+ stakesSource
January 21, 2026Stake report, Schedule 13G/A, by BlackRock, Inc.6.6% of the class5%+ stakesSource
November 14, 2025Stake report, Schedule 13G/A, by Cadian Capital Management, LP7.7% of the class5%+ stakesSource
November 4, 2025Stake report, Schedule 13G/A, by Mirabella Financial Services LLP7.69% of the class5%+ stakesSource

Selling to them or working with them? See who runs Maxcyte, Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on Maxcyte, Inc. and the records around it.

Maxcyte, Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on Maxcyte, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Maxcyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Maxcyte, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    14 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

The newest 12 of 14 records.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-03-27InChief Financial Officer2026-03-308-K, 2026-03-27

Who leads Maxcyte, Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to Maxcyte, Inc.?

New leaders reset buying decisions — get the Full Report on Maxcyte, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch Maxcyte, Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Financial Officer at Maxcyte, Inc., with the record behind each one.

Find candidates like Chief Financial Officer at Maxcyte, Inc.

Every change, in the filing's words

Filed 2026-03-27 · 8-K

Appointed: Parmeet Ahuja, Chief Financial Officer, effective 2026-03-30

On March 23, 2026, the Board of Directors (the " Board ") of MaxCyte, Inc. (the " Company ") appointed Parmeet Ahuja as the Company's Chief Financial Officer, effective March 30, 2026.

Also stated in this filing

  • Mr. Ahuja will also serve as the Company's principal accounting officer.
  • Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025.
  • Prior to joining MaxCyte, Mr. Ahuja, 57, served as Vice President, Investor Relations of Agilent Technologies, Inc., a life sciences tools company, ("Agilent") from August 2021 to October 2025, and previously served as Vice President, Financial Planning and Analysis, Operations and Supply Chain at Agilent from July 2017 to July 2021.
  • Mr. Ahuja brings over 20 years of finance leadership experience across a global, publicly traded, life sciences organization.
  • Previously, he held several leadership roles at Agilent in operational finance, financial planning and analysis, enterprise audit and controls, and global financial operations.
  • Mr. Ahuja holds an MBA from San Jose State University and a Bachelor of Commerce (Hons) from Delhi University.
  • Mr. Ahuja will receive an annual base salary of $450,000 and will be eligible to receive an annual cash performance bonus with an initial target bonus percentage equal to 50% of his base salary.

Tools for this story

Each opens in a new tab, filled in for Maxcyte, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/maxcyte
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Maxcyte, Inc. names Parmeet Ahuja CFO (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/maxcyte